Argos Therapeutics Inc (NASDAQ:ARGS)’s share price traded down 19% on Monday after Stifel Nicolaus lowered their price target on the stock to $1.20. Stifel Nicolaus currently has a hold rating on the stock. Argos Therapeutics traded as low as $1.00 and last traded at $0.81, with a volume of 742,392 shares traded. The stock had previously closed at $1.00.
Other equities analysts also recently issued research reports about the stock. Needham & Company LLC downgraded shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 22nd. FBR & Co reiterated a “hold” rating on shares of Argos Therapeutics in a report on Thursday, February 23rd. JMP Securities downgraded shares of Argos Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 22nd. Finally, Zacks Investment Research upgraded shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a report on Monday, January 16th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Argos Therapeutics currently has an average rating of “Hold” and a consensus target price of $8.03.
Several large investors have recently modified their holdings of ARGS. Sanders Morris Harris Inc. boosted its stake in shares of Argos Therapeutics by 109.9% in the third quarter. Sanders Morris Harris Inc. now owns 241,512 shares of the biopharmaceutical company’s stock worth $1,201,000 after buying an additional 126,475 shares during the last quarter. Wasatch Advisors Inc. boosted its stake in shares of Argos Therapeutics by 35.2% in the third quarter. Wasatch Advisors Inc. now owns 3,228,741 shares of the biopharmaceutical company’s stock worth $16,047,000 after buying an additional 840,260 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Argos Therapeutics by 11.7% in the fourth quarter. State Street Corp now owns 177,494 shares of the biopharmaceutical company’s stock worth $870,000 after buying an additional 18,625 shares during the last quarter. 15.25% of the stock is currently owned by institutional investors and hedge funds.
The stock’s market cap is $35.06 million. The company has a 50 day moving average price of $2.93 and a 200 day moving average price of $4.34.
Your IP Address:
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.